Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$115.01
+0.0%
$114.84
$107.07
$160.27
$32.49B1.222.13 million shs2.04 million shs
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$160.76
+0.3%
$167.78
$132.58
$228.88
$7.72B1.44911,877 shs588,576 shs
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$168.28
+0.2%
$169.83
$134.65
$247.04
$28.02B1.181.80 million shs1.79 million shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$48.21
$52.14
$43.19
$72.16
$7.55B1.413.36 million shs2.54 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
0.00%+2.64%-0.51%-7.55%+5.89%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.00%+7.26%-5.38%-3.37%+17.55%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
0.00%-2.65%+3.57%+2.15%+22.87%
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.00%+8.51%-11.01%-16.30%+3.06%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$115.01
+0.0%
$114.84
$107.07
$160.27
$32.49B1.222.13 million shs2.04 million shs
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$160.76
+0.3%
$167.78
$132.58
$228.88
$7.72B1.44911,877 shs588,576 shs
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$168.28
+0.2%
$169.83
$134.65
$247.04
$28.02B1.181.80 million shs1.79 million shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$48.21
$52.14
$43.19
$72.16
$7.55B1.413.36 million shs2.54 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
0.00%+2.64%-0.51%-7.55%+5.89%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.00%+7.26%-5.38%-3.37%+17.55%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
0.00%-2.65%+3.57%+2.15%+22.87%
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.00%+8.51%-11.01%-16.30%+3.06%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
3.00
Buy$163.7142.35% Upside
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.60
Moderate Buy$207.6929.19% Upside
IQVIA Holdings Inc. stock logo
IQV
IQVIA
3.00
Buy$225.6934.11% Upside
Bio-Techne Corp stock logo
TECH
Bio-Techne
2.79
Moderate Buy$65.9236.74% Upside

Current Analyst Ratings Breakdown

Latest CRL, TECH, A, and IQV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
Set Price TargetOutperform$62.00
5/14/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
UpgradeModerate Buy
5/11/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
DowngradeSell (D)Sell (E+)
5/8/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Set Price Target$213.00
5/8/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Reiterated RatingOutperform$220.00
5/8/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Set Price Target$192.00
5/8/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Boost Price TargetOverweight$210.00 ➝ $220.00
5/7/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
UpgradeSell (D+)Hold (C-)
5/7/2026
IQVIA Holdings Inc. stock logo
IQV
IQVIA
Set Price Target$225.00
5/7/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
Set Price Target$50.00
5/7/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
Set Price Target$50.00
(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$6.95B4.68$6.63 per share17.34$23.78 per share4.84
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.02B1.93$22.02 per share7.30$61.17 per share2.63
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$16.31B1.72$17.90 per share9.40$38.04 per share4.42
Bio-Techne Corp stock logo
TECH
Bio-Techne
$1.22B6.19$2.44 per share19.72$13.32 per share3.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$1.30B$4.5325.3917.562.4218.26%24.49%12.83%5/27/2026 (Estimated)
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-$144.34M-$3.76N/A13.401.83-4.59%15.36%6.61%8/5/2026 (Estimated)
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$1.36B$8.0720.8513.021.618.33%30.50%6.53%7/28/2026 (Estimated)
Bio-Techne Corp stock logo
TECH
Bio-Techne
$73.40M$0.6969.8726.343.759.05%13.57%10.66%8/5/2026 (Estimated)

Latest CRL, TECH, A, and IQV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/27/2026Q2 2026
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$1.40N/AN/AN/A$1.80 billionN/A
5/7/2026Q1 2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$1.96$2.06+$0.10-$0.30$977.46 million$995.83 million
5/6/2026Q3 2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.55$0.53-$0.02$0.32$316.11 million$311.42 million
5/5/2026Q1 2026
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$2.83$2.90+$0.07$1.61$4.10 billion$4.15 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$1.020.89%+6.58%22.52%9 Years
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
IQVIA Holdings Inc. stock logo
IQV
IQVIA
N/AN/AN/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.320.66%N/A46.38%N/A

Latest CRL, TECH, A, and IQV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/20/2026
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
quarterly$0.25500.9%6/30/20266/30/20267/22/2026
5/6/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
quarterly$0.080.72%5/18/20265/18/20265/29/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
0.44
2.07
1.59
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.90
1.36
1.03
IQVIA Holdings Inc. stock logo
IQV
IQVIA
2.20
0.75
0.75
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.10
4.49
3.18

Institutional Ownership

CompanyInstitutional Ownership
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
89.62%
Bio-Techne Corp stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.30%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
1.70%
Bio-Techne Corp stock logo
TECH
Bio-Techne
1.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
18,100282.60 millionN/AOptionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
19,70048.17 million47.54 millionOptionable
IQVIA Holdings Inc. stock logo
IQV
IQVIA
93,000166.90 million164.06 millionOptionable
Bio-Techne Corp stock logo
TECH
Bio-Techne
3,100156.57 million154.53 millionOptionable

Recent News About These Companies

2 Healthcare Stocks to Research Further and 1 We Find Risky
CMB.TECH NV (CMBT) Q1 2026 Earnings Call Transcript
Bio-Techne Corp TE1
Bio-Techne (TECH) Q3 2026 Earnings Transcript
Bio-Techne Q3 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Agilent Technologies stock logo

Agilent Technologies NYSE:A

$115.01 +0.05 (+0.04%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$114.22 -0.79 (-0.69%)
As of 05/22/2026 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$160.76 +0.46 (+0.29%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$160.32 -0.45 (-0.28%)
As of 05/22/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

IQVIA stock logo

IQVIA NYSE:IQV

$168.28 +0.38 (+0.23%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$167.93 -0.35 (-0.21%)
As of 05/22/2026 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$48.21 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$48.10 -0.11 (-0.23%)
As of 05/22/2026 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.